Suchergebnisse - "Wolchok, Jedd D"

Cancer immunotherapy using checkpoint blockade von Ribas, Antoni, Wolchok, Jedd D

“… The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting …”
Weitere Angaben

The many faces of the anti-COVID immune response von Vardhana, Santosha A, Wolchok, Jedd D

“… The novel 2019 strain of coronavirus is a source of profound morbidity and mortality worldwide. Compared with recent viral outbreaks, COVID-19 infection has a …”
Weitere Angaben

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations von Zou, Weiping, Wolchok, Jedd D, Chen, Lieping

“… PD-L1 and PD-1 (PD) pathway blockade is a highly promising therapy and has elicited durable antitumor responses and long-term remissions in a subset of …”
Weitere Angaben

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies von Zappasodi, Roberta, Merghoub, Taha, Wolchok, Jedd D

“… Checkpoint blockade has formally demonstrated that reactivating anti-tumor immune responses can regress tumors. However, this only occurs in a fraction of …”
Weitere Angaben

Immune Checkpoint Blockade in Cancer Therapy von Postow, Michael A, Callahan, Margaret K, Wolchok, Jedd D

“… Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 …”
Weitere Angaben

Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways von Kraehenbuehl, Lukas, Weng, Chien-Huan, Eghbali, Shabnam, Wolchok, Jedd D, Merghoub, Taha

“… The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as …”
Volltext

Immunotherapy of Melanoma: Facts and Hopes von Weiss, Sarah A, Wolchok, Jedd D, Sznol, Mario

“… Melanoma is among the most sensitive of malignancies to immune modulation. Although multiple trials conducted over decades with vaccines, cytokines, and cell …”
Weitere Angaben

The future of cancer immunotherapy: microenvironment-targeting combinations von Murciano-Goroff, Yonina R., Warner, Allison Betof, Wolchok, Jedd D.

“… Immunotherapy holds the potential to induce durable responses, but only a minority of patients currently respond. The etiologies of primary and secondary …”
Volltext

Targeting T Cell Co-receptors for Cancer Therapy von Callahan, Margaret K, Postow, Michael A, Wolchok, Jedd D

“… Checkpoint-blocking antibodies can generate potent anti-tumor responses by encouraging the immune system to seek and destroy cancer cells. At this time, the …”
Weitere Angaben

At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy von Callahan, Margaret K., Wolchok, Jedd D.

“… Clinical Review for Basic Researchers: Treating patients with CTLA‐4 and PD‐1 pathway blocking antibodies, plus clinical progress and application of agents in …”
Volltext

The hallmarks of successful anticancer immunotherapy von Galluzzi, Lorenzo, Chan, Timothy A, Kroemer, Guido, Wolchok, Jedd D, López-Soto, Alejandro

“… Immunotherapy is revolutionizing the clinical management of multiple tumors. However, only a fraction of patients with cancer responds to immunotherapy, and …”
Weitere Angaben

TNF in the era of immune checkpoint inhibitors: friend or foe? von Chen, Allen Y, Wolchok, Jedd D, Bass, Anne R

“… Immune checkpoint inhibitors (ICIs) are effective in the treatment of patients with advanced cancer and have emerged as a pillar of standard cancer care …”
Volltext

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy von Khalil, Danny N., Smith, Eric L., Brentjens, Renier J., Wolchok, Jedd D.

“… Key Points Cancer immunotherapies have the potential to generate robust antitumour responses; this can be achieved through several methods, such as modulatory …”
Volltext

Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner von Holmgaard, Rikke B., Zamarin, Dmitriy, Li, Yanyun, Gasmi, Billel, Munn, David H., Allison, James P., Merghoub, Taha, Wolchok, Jedd D.

“… Indoleamine 2,3-dioxygenase (IDO) has been described as a major mechanism of immunosuppression in tumors, though the mechanisms of this are poorly understood …”
Volltext

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma von Schadendorf, Dirk, Hodi, F Stephen, Robert, Caroline, Weber, Jeffrey S, Margolin, Kim, Hamid, Omid, Patt, Debra, Chen, Tai-Tsang, Berman, David M, Wolchok, Jedd D

“… To provide a more precise estimate of long-term survival observed for ipilimumab-treated patients with advanced melanoma, we performed a pooled analysis of …”
Weitere Angaben

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis von Dubin, Krista, Callahan, Margaret K., Ren, Boyu, Khanin, Raya, Viale, Agnes, Ling, Lilan, No, Daniel, Gobourne, Asia, Littmann, Eric, Huttenhower, Curtis, Pamer, Eric G., Wolchok, Jedd D.

“… The composition of the intestinal microbiota influences the development of inflammatory disorders. However, associating inflammatory diseases with specific …”
Volltext

Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody von Iwama, Shintaro, De Remigis, Alessandra, Callahan, Margaret K, Slovin, Susan F, Wolchok, Jedd D, Caturegli, Patrizio

“… Hypophysitis is a chronic inflammation of the pituitary gland of unknown (primary forms) or recognizable (secondary forms) etiology, such as the use of …”
Weitere Angaben

Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine von Campesato, Luis Felipe, Budhu, Sadna, Tchaicha, Jeremy, Weng, Chien-Huan, Gigoux, Mathieu, Cohen, Ivan Jose, Redmond, David, Mangarin, Levi, Pourpe, Stephane, Liu, Cailian, Zappasodi, Roberta, Zamarin, Dmitriy, Cavanaugh, Jill, Castro, Alfredo C., Manfredi, Mark G., McGovern, Karen, Merghoub, Taha, Wolchok, Jedd D.

“… Tryptophan catabolism by the enzymes indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2 (IDO/TDO) promotes immunosuppression across different …”
Volltext

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade von Benci, Joseph L, Johnson, Lexus R, Choa, Ruth, Xu, Yuanming, Qiu, Jingya, Zhou, Zilu, Xu, Bihui, Ye, Darwin, Nathanson, Katherine L, June, Carl H, Wherry, E John, Zhang, Nancy R, Ishwaran, Hemant, Hellmann, Matthew D, Wolchok, Jedd D, Kambayashi, Taku, Minn, Andy J

“… Interferon-gamma (IFNG) augments immune function yet promotes T cell exhaustion through PDL1. How these opposing effects are integrated to impact immune …”
Weitere Angaben

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial von Hodi, Frank Stephen, Chiarion-Sileni, Vanna, Gonzalez, Rene, Grob, Jean-Jacques, Rutkowski, Piotr, Cowey, Charles Lance, Lao, Christopher D, Schadendorf, Dirk, Wagstaff, John, Dummer, Reinhard, Ferrucci, Pier Francesco, Smylie, Michael, Hill, Andrew, Hogg, David, Marquez-Rodas, Ivan, Jiang, Joel, Rizzo, Jasmine, Larkin, James, Wolchok, Jedd D

“… Previously reported results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free survival, and …”
Volltext